Clinical Trials Logo
  1. Home
  2. Cancer of the Head and Neck
  3. NCT00256295

Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer

Cancer of the Head and Neck Clinical Trial

Official title:
A Phase II Study of Weekly Oxaliplatin and Gemcitabine Combination Chemotherapy for Recurrent or Metastatic Head and Neck Cancer

Clinical Trial Summary

The combination of oxaliplatin and gemcitabine is highly active in a wide variety of tumors including pancreatic, germ cell, breast, biliary, mesothelioma (Mitchell et al, 2002), and lung. In the last study which utilized days 1 and 8 gemcitabine 1000 mg/m2 and days 1 and 8 oxaliplatin 65 mg/m2 in poor prognosis lung cancer patients (PS 1-3) the response rate was 16% with no incidence of febrile neutropenia.

Toxicity is a crucial consideration when designing regimens intended for palliation. Toxicities associated with cisplatin can make it difficult to use in patients with Head and Neck Cancer (HNC), many of whom are elderly and have comorbidities. In addition, many patients with metastatic HNC have previously received cisplatin during neoadjuvant/adjuvant therapy, or as part of their primary chemoradiation treatment. When these patients recur, it is possible their tumors have innate or acquired cisplatin resistance. Oxaliplatin is likely to be better tolerated than cisplatin containing regimens, especially with regards to neurotoxicity. Gemcitabine has shown promising activity as a single agent and in combination chemotherapy in the first line treatment of patients with HNC. A combination chemotherapy regimen using oxaliplatin and gemcitabine administered once every week is logical and worth exploring in patients with metastatic and recurrent head and neck cancer to improve the toxicity profile and patient monitoring while maintaining efficacy of the chemotherapy regimen.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00256295
Study type Interventional
Source University of California, Irvine
Contact
Status Terminated
Phase Phase 2
Start date April 2005
Completion date October 2011
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04444869 - Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer Phase 2
Terminated NCT01370876 - Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Terminated NCT03297957 - Fluorescence Imaging in Head and Neck Cancer N/A
Completed NCT00716157 - Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation N/A
Recruiting NCT04880148 - The Effectiveness of a Thyme and Honey Spray for Oral Toxicities N/A
Completed NCT01017224 - DAHANCA 24: Prognostic Value of 18F-FAZA in Head and Neck Squamous Cell Carcinoma (HNSCC) N/A
Completed NCT00496652 - DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC Phase 3
Completed NCT00798655 - Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer Phase 2
Recruiting NCT03620084 - Effects of Expiratory Muscle Strength Training on Airway Protection and Swallowing in Chronic Dysphagia After Radiation Therapy N/A
Completed NCT00147472 - Positronic Emission Tomography (PET) Imaging in Post Radiation Evaluation of Head and Neck Tumours (PET PREVENT Trial) Phase 3
Completed NCT02880072 - Absorption of Orally Ingested Phosphate in Refeeding Syndrome Phase 4
Completed NCT01917942 - Radiotherapy With Humidification in Head And Neck Cancer Phase 3
Recruiting NCT04865731 - Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer Phase 2
Completed NCT02442336 - A Web-Based Multimedia Intervention for Head and Neck Cancer Patients N/A
Completed NCT03102229 - Real-time Activity Monitoring to Prevent Admissions During RadioTherapy N/A
Completed NCT00474825 - Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck Phase 1
Recruiting NCT00180921 - Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck Phase 2
Completed NCT01283334 - A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer Phase 1/Phase 2
Recruiting NCT02557048 - Head and Neck Cancer in Children: A Retrospective Study
Completed NCT02073032 - Incidence and Risk Factors of Refeeding Syndrome N/A